The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

  NAMES OF REPORTING PERSONS

  Sumitomo Chemical Co., Ltd.

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

  (a)  ☐        (b)  ☐

  SEC USE ONLY

  SOURCE OF FUNDS (See Instructions)

  OO

   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

  ☐

  CITIZENSHIP OR PLACE OF ORGANIZATION

  Japan

NUMBER OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH:

  SOLE VOTING POWER

  SHARED VOTING POWER

  45,396,404

  SOLE DISPOSITIVE POWER

  SHARED DISPOSITIVE POWER

  45,396,404

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

  45,396,404

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

  ☐

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

  50.56% (1)

  TYPE OF REPORTING PERSON

  CO

This calculation is based on 89,788,054 Common Shares, $0.000017727 par value per share, of the Issuer (as defined below), issued and outstanding as of January 31, 2020, as disclosed by the Issuer on its quarterly report on Form 10-Q, as filed with the Securities and Exchange Commission on February 10, 2020.

  NAMES OF REPORTING PERSONS

  Sumitomo Dainippon Pharma Co., Ltd.

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

  (a)  ☐        (b)  ☐

  SEC USE ONLY

  SOURCE OF FUNDS

  WC

   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

  ☐

  CITIZENSHIP OR PLACE OF ORGANIZATION

  Japan

NUMBER OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH:

  SOLE VOTING POWER

  SHARED VOTING POWER

  45,396,404

  SOLE DISPOSITIVE POWER

  SHARED DISPOSITIVE POWER

  45,396,404

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

  45,396,404

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

  ☐

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

  50.56% (2)

  TYPE OF REPORTING PERSON

  CO

Working capital from Sumitomo Dainippon Pharma Co., Ltd. was contributed to Sumitovant Biopharma Ltd. for purposes of acquiring additional shares.

This calculation is based on 89,788,054 Common Shares, $0.000017727 par value per share, of the Issuer (as defined below), issued and outstanding as of January 31, 2020, as disclosed by the Issuer on its quarterly report on Form 10-Q, as filed with the Securities and Exchange Commission on February 10, 2020.

  NAMES OF REPORTING PERSONS

  Sumitovant Biopharma Ltd.

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

  (a)  ☐        (b)  ☐

  SEC USE ONLY

  SOURCE OF FUNDS

  OO

   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

  ☐

  CITIZENSHIP OR PLACE OF ORGANIZATION

  Bermuda

NUMBER OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH:

  SOLE VOTING POWER

  45,396,404

  SHARED VOTING POWER

  SOLE DISPOSITIVE POWER

  45,396,404

  SHARED DISPOSITIVE POWER

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

  45,396,404

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

  ☐

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

  50.56% (1)

  TYPE OF REPORTING PERSON

  OO

This calculations is based on 89,788,054 Common Shares, $0.000017727 par value per share, of the Issuer (as defined below), issued and outstanding as of January 31, 2020, as disclosed by the Issuer on its quarterly report on Form 10-Q, as filed with the Securities and Exchange Commission on February 10, 2020.

Source and Amount of Funds or Other Consideration

Purpose of Transaction

Interest in Securities of the Issuer

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Material to be Filed as Exhibits.

  Dated: March 18, 2020

  Dated: March 18, 2020

Senior Director

Global Corporate Strategy

  Dated: March 18, 2020

CGMI is hereby appointed by the Company to act on behalf and for the benefit of the Company to purchase Securities in accordance with the terms of this Purchase Plan.

Purchases made by CGMI pursuant to this Purchase Plan shall be made at the prevailing market prices in open-market transactions in accordance with the customary principles of best execution. CGMI will use its best efforts to effect such purchases in accordance with the provisions of clauses (b)(2), (b)(3), (b)(4) and (c) of Rule 10b-18; subject to any delays between the execution and reporting of a trade of the Securities on the Principal Market and other circumstances beyond CGMI’s control.

The parameters of any agreed purchases, as set forth in Appendix A, shall be adjusted by CGMI, in good faith and in a commercially reasonable manner, to take into account the occurrence of any dilutive or concentrative event with respect to the Securities, including but not limited to any share split, reverse share split or share dividend, or any change in capitalization with respect to Myovant, that occurs during the term of this Purchase Plan.

Any payments and deliveries with respect to the Securities purchased by CGMI pursuant to this Purchase Plan, including any applicable fees calculated in accordance with the terms of Appendix A, shall be effected in accordance with the terms set forth in Appendix A.

Purchased Securities will be held or delivered by CGMI or its affiliates in accordance with instructions to be furnished by the Company.

Material Non-Public Information. As of the date hereof, the Company is not aware of any material, non-public information with respect to Myovant or the Securities. The Company is entering into this Purchase Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1, Rule 10b-18 or other applicable securities laws. The Company is not entering into this Purchase Plan (i) in anticipation of, in connection with, or to facilitate, a distribution of its securities, a self-tender offer or a third-party tender offer; or (ii) to create actual or apparent trading activity in the Securities (or any security convertible into or exchangeable for the Securities) or to raise or depress or otherwise manipulate the price of the Securities (or any security convertible into or exchangeable for the Securities).

Corporate Authorization. Purchases of Securities under this Purchase Plan have been duly authorized by the Company and are not prohibited by any legal, regulatory or contractual restrictions or undertakings binding on the Company. The Company will inform CGMI as soon as possible of any subsequent legal or contractual restrictions affecting the execution of this Purchase Plan by CGMI or the Company and of the occurrence of any event that would cause this Purchase Plan to be suspended or to end as contemplated in Section C and Section E.

Enforceability. This Purchase Plan, as supplemented by Appendix A, constitutes the Company’s legal, valid and binding obligation enforceable against the Company in accordance with its terms. There is no litigation, arbitration or other proceeding pending, or to Company’s knowledge threatened, that would prevent or interfere with the Company’s purchase of Securities under this Purchase Plan.

[Intentionally Omitted]¹

[Intentionally Omitted]²

Merger Announcements. Company will promptly (but in any event prior to the next opening of the regular trading session on the Principal Market) notify CGMI of any public announcement (as defined in Rule 165(f) under the Securities Act of 1933, as amended (the “Securities Act”)) of any Merger Transaction (as defined in Appendix A) or potential Merger Transaction that the Company becomes aware of.

Corresponding Hedging Transactions. The Company represents that it has not entered, and during the Plan Period, without the prior written consent of CGMI, will not enter, directly or indirectly, into any hedging or other derivative transaction with respect to the Securities.

Volume Limitation Information. The Company agrees to provide CGMI with all necessary information regarding the Company’s previous purchases, as may be required by CGMI, in order to calculate relevant volume limitations applicable to the Company under Rule 10b-18(b)(4).

Compliance with Laws. The Company agrees that it will not take any action that would cause any purchase of Securities under this Purchase Plan not to comply with Rule 10b-18 or any other applicable law (including, without limitation the Securities Act and the Exchange Act).

Manner of Purchase. Subject to the terms of this Purchase Plan, as set forth herein (including Appendix A), CGMI shall have full discretion with respect to the execution of all purchases and the Company agrees that it does not have authority, influence or control over any purchase of Securities effected by CGMI pursuant to this Purchase Plan and will not attempt to exercise any such authority, influence or control.

Parties’ Relationship. The Company acknowledges and agrees that, in purchasing Securities pursuant to this Purchase Plan, CGMI will not be acting as the Company’s trustee or fiduciary or in any other similar capacity.

NTD: Not relevant for a third-party 10b5-1 plan.

NTD: Not relevant for a third-party 10b5-1 plan.

Bankruptcy Code. The Company acknowledges and agrees that this Purchase Plan is a “securities contract,” as such term is defined in Section 741(7) of Title 11 of the United States Code, as it may be amended (the “Bankruptcy Code”), and the parties hereto are entitled to all of the protections given such contracts under the Bankruptcy Code. The Company is not “insolvent” (as such term is defined under Section 101(32) of the Bankruptcy Code and the Company would be able to purchase a number of Securities with a value equal to the Target Repurchase Amount in compliance with the laws of the jurisdiction of Company’s incorporation.

Financial Expertise and Total Assets. The Company (i) is capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities; (ii) will exercise independent judgment in evaluating the recommendations of any broker-dealer or its associated persons, unless it has otherwise notified the broker-dealer in writing; and (iii) has total assets with a fair market value of at least USD 50,000,000 as of the date hereof.

Certificates and Other Documentation. The Company agrees to provide CGMI with certificates (and other documentation reasonably requested by CGMI) that identify, and include specimen signatures of, all individuals (“Authorized Persons”) authorized to establish, maintain, transact in and instruct CGMI on the brokerage account to be established for the purpose of effecting purchases of Securities on behalf of the Company.

Tax Forms. The Company agrees to provide CGMI with any and all relevant forms certifying the taxpayer identification number and other relevant information of the entity purchasing the Securities.

CGMI determines, in its sole discretion, that it is appropriate for CGMI or its affiliates to refrain from purchasing Securities, on behalf and for the benefit of the Company, in accordance with any legal, contractual, regulatory or self-regulatory requirements or related policies and procedures (whether or not such requirements, policies or procedures are imposed by law or have been voluntarily adopted by CGMI or its affiliates) applicable to it or its affiliates;

CGMI receives any notice from the Company with respect to matters contemplated by Section B.6 above; or

CGMI determines, in its sole discretion, that a Market Disruption Event (as defined in Appendix A) has occurred.

The occurrence of the close of trading on the Principal Market on the Completion Date³ (as defined in Appendix A) under clause (i) of the definition thereof;

The Company or its designee notifies CGMI, upon one business day’s written notice, that this Purchase Plan is to be terminated; provided that the Company or its designee shall only deliver such notification in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1, Rule 10b-18 or other applicable securities laws;

CGMI decides to terminate the Purchase Plan in connection with its determination that any of the events specified in Section C above occurred on three (3) consecutive Scheduled Trading Days (as defined in Appendix A)⁴;

CGMI becomes aware of the commencement of any voluntary or involuntary case or other proceeding seeking liquidation, reorganization or other relief under any bankruptcy, insolvency or similar law or seeking the appointment of a trustee, receiver or other similar official, in each case with respect to the Company or the taking of any corporate action by the Company to authorize or commence any of the foregoing; or

CGMI decides, in its sole discretion, to terminate the Purchase Plan in connection with the public announcement by Myovant or any other person of a tender or exchange offer with respect to the Securities or a merger, acquisition, reorganization, recapitalization or other similar business combination or transaction, as a result of the consummation of which, the Securities would be exchanged or converted into cash, securities or other property.

The Company agrees to indemnify and hold harmless CGMI (and its directors, officers, employees and affiliates) from and against all claims, liabilities, losses, damages and expenses (including reasonable attorney’s fees and costs) arising out of or attributable to (a) any breach by the Company of this Purchase Plan (including the Company’s representations, warranties and undertakings), and (b) any violation by the Company of any applicable laws or regulations related to this Purchase Plan. The Company will have no indemnification obligations in the case of gross negligence or willful misconduct of CGMI or any other indemnified person. This indemnification will survive the termination of this Purchase Plan.

Notwithstanding any other provision herein, neither CGMI nor the Company will be liable for:

NTD: Completion Date is not defined in Appendix A.

NTD: Scheduled Trading Days are not defined in Appendix A.

Special, indirect, punitive, exemplary, or consequential damages, or incidental losses or damages of any kind, even if advised of the possibility of such losses or damages or if such losses or damages could have been reasonably foreseen; or

Any failure to perform or for any delay in performance that results from a cause or circumstance that is beyond its reasonable control, including but not limited to failure of electronic or mechanical equipment, strikes, failure of common carrier or utility systems, severe weather, market disruptions or other causes commonly known as “acts of God”.

The Company acknowledges and agrees that CGMI has not provided the Company with any tax, accounting or legal advice with respect to this Purchase Plan, including whether the Company would be entitled to any of the affirmative defenses under Rule 10b5-1.

/s/ Marianne L. Romeo

/s/ Robert G. Leonard

Order 1: Purchase up to the Rule 10b-18 maximum allowable volume (including pursuant to “block” purchases as permitted under the Rule) at a maximum price of $15.00 each day until 1,500,000 shares have been purchased in the aggregate

Order 2: Purchase up to $800,000 per day, subject to the incremental limit orders in the grid. As purchases are executed throughout a given day, they shall be allocated to the lowest-priced available limit order that they satisfy.

Limit Price

$15.00

$14.00

$13.00

$12.00

$11.00